Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$64.08M+138.73%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Farquhar
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 843
- Beta
- 2.02
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 34.97
Financials
HTFL has only 10 quarterly periods on file — the charts below show the full history available.
Revenue
$64.08M+138.7%Net Income
$-15.74MEBITDA
$-15.72MFree Cash Flow
$-10.50MEPS (diluted)
$-0.18Shares Outstanding (diluted)
86.40M+35.3%Operating Expenses
$71.09MCash & Debt
$162.55MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $176.03M | $-116.79M | $-1.37 |
| 2024 | $125.81M | $-96.43M | $-1.53 |
| 2023 | $87.17M | $-95.66M | $-1.94 |
Valuation
HTFLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-67.39%Social Signal Score
Mentions (10)
- News (RSS)investing·17d ago·Neutral
Heartflow Inc stock hits all-time high at 51.78 USD
View source ↗ - News (RSS)seekingalpha·24d ago·Neutral
HeartFlow, Inc. (HTFL) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow
View source ↗ - Newsfool.com·30d ago·Negative
HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High The sale of 33,416 shares generated a total value of approximately $1.7 million based on a weighted average execution price of $49.85. The traded shares represent 13% of the equity stake held by the officer before the transaction.
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting Appropriate Use Criteria for cath lab referrals FUSION trial presented at ESC and published in Journal of the American College of Cardi
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference SAN FRANCISCO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Wells Fargo 21st Annual Healthcare Conference. The fireside chat, which will include a slideshow presentation followed by a question-and-answer ses…
View source ↗ - Newsseekingalpha.com·50d ago·Neutral
HeartFlow: An Impressive MedTech Growth Play HeartFlow delivered a convincing Q2 with 48% sales growth and gross margins rising to 83%, driving strong market optimism. The company raised full-year revenue guidance to $246–$250 million, though the outlook appears conservative given recent momentum and sequential growth. Shares now trade at 13x sales, supported by accelerating topline growth, expanding plaque-related revenue, and commercial adoption of its non-invasive cardiac solution.
View source ↗ - Newsfool.com·52d ago·Negative
Why Heartflow Stock Soared Today Heartflow's AI-powered platform could save countless lives. The company is growing at an impressive clip.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·53d ago·Neutral
Heartflow Q2 Earnings Call Highlights Heartflow NASDAQ: HTFL reported second-quarter revenue of $64.1 million, up 48% from a year earlier, as growth in its Plaque Analysis offering, durable FFR-CT utilization and continued expansion of the coronary CT angiography, or CCTA, market supported results.
View source ↗ - Newszacks.com·53d ago·Neutral
HeartFlow (HTFL) Reports Q2 Loss, Beats Revenue Estimates HeartFlow (HTFL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $1.46 per share a year ago.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.10 per share
Typical surprise +25.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.07 vs $-0.13beat
- Thu, May 14$-0.16 vs $-0.19beat
- Wed, Mar 18$-0.12 vs $-0.19beat
- Wed, Nov 12$-0.27 vs $-0.20miss
- Fri, Sep 19$-0.06 vs $-0.21beat
- Thu, Jul 17$-0.46 vs $-0.21miss
Estimates and results for HTFL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HTFL officers and directors.
- Bought
- —
- Sold
- $79.0m
0 trades
30 trades
- Rogers Campbellsold
- Verghese Vikramsold
- Verghese Vikramsold
- Verghese Vikramsold
- Verghese Vikramsold
- Verghese Vikramsold
- Farquhar John C.m.sold
- Farquhar John C.m.sold
70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HTFL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.